BIO, FDA talk new reform agenda

WASHINGTON - Fourteen biotech CEOs met last week with FDA Commissioner David Kessler to discuss proposals for speeding early-stage drug development, providing some optimism that the door to administrative reform remains open at the agency.

Meanwhile, House Commerce Committee Chairman Thomas Bliley announced dates for hearings on the agency and suggested that the House Republican leadership finally will introduce reform legislation soon...